Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.
about
Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.Total joint replacement in patients with inhibitors.Haemophilia therapies.Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives.Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors.New assays for monitoring haemophilia treatment.Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Thrombin generation testing in haemophilia comprehensive care centres.Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery.A century of heparin: past, present and future.Optimization of the thrombin generation test components to measure potency of factor VIII concentrates.The utility of thromboelastography in inherited and acquired bleeding disorders.Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model.Coagulation deficiencies: a look to the future.Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors.An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.Optimal monitoring of bypass therapy in hemophilia A patients with inhibitors by the use of clot waveform analysis.Evaluation of the use of global haemostasis assays to monitor treatment in factor XI deficiency.Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.Biochemical characterization of LR769, a new recombinant factor VIIa bypassing agent produced in the milk of transgenic rabbits.Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.Hemostatic treatment using factor VIII concentrates for neutralizing high-responding inhibitors prior to CVAD insertion for immune-tolerance induction therapy.Evaluation of prophylactic therapy in haemophilia with global coagulation tests.Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.How I treat inhibitors in haemophilia.Global haemostasis and point of care testing.In vitro comparison of the effect of two factor XI (FXI) concentrates on thrombin generation in major FXI deficiency.Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents.Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study.Recollections on thrombin generation.The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin.Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab.
P2860
Q36410051-875605D0-49A2-48EF-B4F8-835C78B8A449Q36473080-C930FBFF-10EE-4B5D-A9E7-822E0D02832FQ36810282-A9194F25-E63A-4891-83A0-65F7AFBDD81AQ36818527-D982317D-59A0-49D7-9B60-6C3640B35AB3Q36985329-E9C39891-DAAF-4175-8C9F-828F6E573B4FQ37169669-AA8E7624-C3CC-42E5-8286-266BAB04AD6FQ37176506-3A30280C-8FC4-4C12-9F54-DAF190293CEFQ37185097-6552CD9A-9DBC-4717-8980-1D82247F9394Q37589662-6A26816C-C764-4697-B875-D40EA9F96A09Q37845931-12F4CE80-A856-4374-BCB4-FA5564614AF9Q38044492-7E253B00-BDE9-4DDD-971F-6B56D1052882Q38793611-CE85B0FC-B833-49B1-9B36-367F58775F0DQ38796270-C07E5137-056C-4D6D-BFF3-A4B94913E895Q38855599-0A543A6C-2F34-4341-894E-C28538C9B9C4Q43180952-69B1C2D5-5594-4BAA-8792-38CA6D01CCDEQ43517013-F752C474-CDA5-4753-8C83-A59853B3C3F8Q44211358-7D4DB895-A6F5-42B1-BE92-2277FA2C22A3Q44950012-6240819B-FE3D-46C2-9180-642F46F96FA0Q45859220-6A8B91A4-2EA3-4189-8722-5282F7C157E8Q45861959-B8FAD968-63F2-43B6-8BDD-924E5EB8F2C4Q45864880-E88E6070-C313-4387-AEBE-AEC3779110DFQ45868639-36CB6929-6409-4B89-8338-13A1904C1A2AQ45869388-6DC2E106-C715-444D-8BB9-8622D4B3AF5DQ45871587-E139893D-9FA3-4A45-8080-81E3EFDE2134Q45873508-E9507C8D-8576-448A-8742-8A9AA6E210F1Q45877685-6F3841BD-3829-4B5A-86DF-B081521EBB70Q45879927-4B644AE1-D0EA-4146-B8C9-3AAF6BA9B3BDQ45879939-A9EFE1AC-0233-4701-B584-63128A0A5D1FQ45880602-E7F85B16-7F86-44D8-AE4B-D6180E7E73D0Q45886119-AEDC8D8F-06E9-42E2-A40C-B39FC1BFF653Q46676476-A54C7C85-D93F-45B1-9F54-D789AB290562Q48538694-33225D33-2426-46B8-B70A-92EC3E299534Q51718916-65E38062-268E-473D-9A49-030410807F36Q52689204-14C21974-5249-4924-8A01-519004FF5587
P2860
Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Major surgery in a severe haem ...... t in the therapeutic decision.
@en
Major surgery in a severe haem ...... t in the therapeutic decision.
@nl
type
label
Major surgery in a severe haem ...... t in the therapeutic decision.
@en
Major surgery in a severe haem ...... t in the therapeutic decision.
@nl
prefLabel
Major surgery in a severe haem ...... t in the therapeutic decision.
@en
Major surgery in a severe haem ...... t in the therapeutic decision.
@nl
P2860
P50
P921
P1433
P1476
Major surgery in a severe haem ...... st in the therapeutic decision
@en
P2093
P2860
P304
P356
10.1111/J.1365-2516.2005.01141.X
P577
2005-09-01T00:00:00Z